|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.640 USD | +0.22% |
|
-3.73% | -33.14% |
| Jun. 10 | Sector Update: Health Care Stocks Higher Tuesday Afternoon | MT |
| Jun. 10 | Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102 | MT |
| Capitalization | 285M 247M 232M 211M 392M 24.71B 443M 2.75B 1.06B 11.34B 1.07B 1.05B 41.78B | P/E ratio 2025 * |
-10.6x | P/E ratio 2026 * | -3.22x |
|---|---|---|---|---|---|
| Enterprise value | -31.62M -27.39M -25.69M -23.42M -43.41M -2.74B -49.11M -305M -117M -1.26B -119M -116M -4.63B | EV / Sales 2025 * |
-0.27x | EV / Sales 2026 * | 1.09x |
| Free-Float |
99.29% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Monte Rosa Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +0.22% | ||
| 1 week | -3.73% | ||
| Current month | +11.00% | ||
| 1 month | +16.88% | ||
| 3 months | -20.00% | ||
| 6 months | -35.01% | ||
| Current year | -33.14% |
| 1 week | 4.37 |  | 4.68 |
| 1 month | 3.9 | | 5.26 |
| Current year | 3.5 | | 7.46 |
| 1 year | 3.21 | | 12.4 |
| 3 years | 2.44 | | 12.62 |
| 5 years | 2.44 | | 45.56 |
| 10 years | 2.44 | | 45.56 |
| Manager | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
CEO | Chief Executive Officer | 54 | 2019-12-31 |
| Chief Operating Officer | - | 2021-02-28 | |
John Castle
CTO | Chief Tech/Sci/R&D Officer | 55 | - |
| Director | Title | Age | Since |
|---|---|---|---|
Markus Warmuth
BRD | Director/Board Member | 54 | 2019-12-31 |
Ali Behbahani
BRD | Director/Board Member | 48 | 2020-03-31 |
| Director/Board Member | 56 | 2020-05-31 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 0% | 9 M€ | +0.92% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.22% | -3.73% | +27.82% | -51.21% | 285M | ||
| +2.05% | +2.32% | +17.59% | +11.70% | 48.77B | ||
| +4.22% | -2.61% | +64.95% | +64.86% | 30.55B | ||
| +0.28% | -2.56% | -28.25% | -26.65% | 26.84B | ||
| -1.97% | -1.73% | -1.96% | +12.51% | 25.49B | ||
| +0.60% | -1.25% | +35.41% | -24.01% | 12.34B | ||
| -37.65% | -60.50% | +22,407.12% | +2,568.32% | 11.72B | ||
| +0.56% | +0.18% | -53.79% | -32.27% | 11.71B | ||
| -3.89% | -8.82% | +129.22% | - | 11.37B | ||
| -0.63% | -1.09% | +37.49% | +92.17% | 10.61B | ||
| Average | -0.75% | -8.47% | +2,263.56% | +290.60% | 18.97B | |
| Weighted average by Cap. | +0.25% | -5.79% | +1,403.97% | +182.50% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 119M 103M 96.36M 87.83M 163M 10.27B 184M 1.14B 439M 4.71B 445M 435M 17.36B | 44.63M 38.67M 36.27M 33.06M 61.28M 3.86B 69.33M 430M 165M 1.77B 167M 164M 6.53B |
| Net income | -34.85M -30.19M -28.32M -25.81M -47.85M -3.02B -54.13M -336M -129M -1.38B -131M -128M -5.1B | -125M -109M -102M -92.95M -172M -10.87B -195M -1.21B -465M -4.99B -471M -461M -18.37B |
| Net Debt | -317M -275M -258M -235M -435M -27.45B -492M -3.05B -1.17B -12.6B -1.19B -1.16B -46.4B | -237M -205M -192M -175M -325M -20.51B -368M -2.28B -878M -9.41B -889M -870M -34.67B |
More financial data
* Estimated data
Employees
142
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-23 | 4.640 $ | +0.22% | 468,074 |
| 25-06-20 | 4.630 $ | +3.12% | 505,514 |
| 25-06-18 | 4.490 $ | -1.75% | 373,757 |
| 25-06-17 | 4.570 $ | -5.19% | 367,894 |
Delayed Quote Nasdaq, June 23, 2025 at 04:00 pm EDT
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.640USD
Average target price
15.75USD
Spread / Average Target
+239.44%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GLUE Stock
Select your edition
All financial news and data tailored to specific country editions
